NEW DELHI: Glenmark Pharmaceuticals today said it has launched Apremilast, the first advanced oral systemic treatment for Psoriasis in India. Apremilast, which is a phosphodiesterase 4 (PDE4) inhibitor indicated for the treatment of moderate to severe Psoriasis, will revolutionise the treatment of Psoriasis, Glenmark Pharmaceuticals said in a statement. The Mumbai-based company has launched Apremilast under the brand name Aprezo. Commenting on the development, Glenmark President and Head India, Middle East and Africa Sujesh Vasudevan said: "With the launch of Apremilast, we are aiming to transform the treatment paradigm for millions of Psoriasis patients in the country." Apremilast is a safer and efficacious treatment which is administered orally thus does not require any paramedic support or routine laboratory monitoring," he added.

Source: Economic Times October 24, 2017 09:45 UTC